Industry Partners

Run your clinical research trial with us

With many years of experience running clinical trials, and as the industry leader in Alzheimer’s research, we have the resources and clinical capabilities to ensure your trials run on time and within budget, whilst collating the highest quality data.

Call Now: 0800 802 1030

"*" indicates required fields

Contact Us

Name*

First Last

Email*

Company Name*

Explore the page

Benefits with Us
Trials
Our Clinics
Blog

Alzheimer's: A Turning Point?

Re:Cognition Health has recently been featured on BBC One’s Panorama, “Alzheimer’s: A Turning Point?”. This follows the journey of volunteers participating in clinical trials, some from Re:Cognition Health’s UK centres, testing new-generation medications designed to slow down the progression of the disease. For those in the UK, you can still watch this on BBC iPlayer.

WHY WORK WITH RE:COGNITION HEALTH?

Rapid set-up and scalable
6 UK locations
Centralised contract and budget negotiation to streamline the process (UK/US)
Clinical Trial Agreement and Budget review within 2 weeks (further acceleration can be requested)
Dedicated start-up team
Length of studies available, from 6 weeks to 3 years and beyond

Trials - A Selection of Case Studies

AACQ, TRAILBLAZER-ALZ 6, AD

Sponsor

Total Treatment Duration

76 Weeks

Number of RCH UK Sites

6

Patients Screened

270

Patients Enrolled

113

Randomization Rate

42%

Sponsor

Eli Lilly Clinical Trials
Abbvie, M23-515

Sponsor

Total Treatment Duration

12 Weeks

Number of RCH UK Sites

3

Patients Screened

25

Patients Enrolled

6

Randomization Rate

24%*

Sponsor

Abbvie
ANAVEX 2-73

Sponsor

Total Treatement Duration

48 Weeks

Number of RCH UK Sites

4

Patients Screened

145

Patients Enrolled

61

Randomization Rate

42%

Sponsor

ANAVEX
GAIN

Sponsor

Total Treatment Duration

48 Weeks

Number of RCH UK Sites

4

Patients Screened

94

Patients Enrolled

36

Randomization Rate

38%

Sponsor

CervoMed
MK1942-008

Sponsor

Total Treatment duration

12 Weeks

Number of RCH UK sites

3

Patients Screened

25

Patients enrolled

14

Randomization rate

56%

Sponsor

MSD
DIMENSION

Sponsor

Total Treatment duration

12 weeks

Number of RCH UK sites

1

Patients Screened

9

Patients enrolled

6

Randomization rate

67%

Sponsor

Sage Therapeutics
BHV3000-404

Sponsor

Total Treatment duration

12 weeks with 12 week open label

Number of RCH UK sites

4

Patients Screened

72

Patients enrolled

29

Randomization rate

40%

SPONSOR

Biohaven
IPX203-B16-02

Sponsor

Total Treatment duration

20 Weeks

Number of RCH UK sites

2

Patients Screened

16

Patients enrolled

11

Randomization rate

69%

Sponsor

Amneal
ACI-7104-PD

Total Treatment duration

74 weeks

Number of RCH UK sites

1

Patients Screened

10

Patients enrolled

8

Randomization rate

80%

Sponsor

AC Immune

Our Clinics

Come and Visit

Our clinics located throughout the UK are set up for your comfort with experts and consultants to walk you through the trial process.

GCSA Certification in the US and Europe

Re:Cognition Health Becomes the First Organisation to Earn Internationally Recognised GCSA Certification in both the US and Europe. The GCSA Certification is a hallmark of quality in clinical research, awarded only to sites that demonstrate adherence to global best-practice standards. This certification was granted following a rigorous assessment conducted by the GCSA Assessment Team at the International Accrediting Organisation for Clinical Research (IAOCR).

Our UK and USA centers are proud to be part
of the PPD Select Partnership Programme.

The Re:Cognition Health UK and US site networks are proud to be preferred sites within the PPD Select Partnership Program of Thermo Fisher Scientific’s PPD clinical research business, a global leader in clinical research. We’re excited about the opportunities this relationship brings, and we are looking forward to working with the PPD Strategic Site Collaborations team and evolving our relationship within the PPD Select Program, across our existing ten sites.